Ironwood Pharma (IRWD) Acquires Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ACN
3. NVDA
4. GOOGL
5. MU
6. DFTX
7. USO
8. APGE
9. ABBV
10. NAVN

Go back to Ironwood Pharma (IRWD) Acquires Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC)

Ironwood Pharma (IRWD) Tops Q3 EPS by 2c

November 4, 2021 7:16 AM EDT

Ironwood Pharma (NASDAQ: IRWD) reported Q3 EPS of $0.33, $0.02 better than the analyst estimate of $0.31. Revenue for the quarter came in at $103.8 million versus the consensus estimate of $105.4 million.

GUIDANCE:

Ironwood Pharma sees FY2021 revenue of $390-410 million, versus the consensus of... More